ArticleJournal of translational autoimmunity2026
Systematic dysregulation of immune-related alternative polyadenylation in systemic lupus erythematosus contributes to patient stratification.
Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alternative polyadenylation (APA) is a common post-transcriptional gene regulatory mechanism. Although dysregulated APA is associated with various human diseases, its role in Systemic Lupus Erythematosus (SLE) remains largely unexplored. We systematically characterized immune-related APA alterations in SLE and investigated their potential for clinically useful patient stratification. Methods: We integrated RNA-seq data from multiple SLE cohorts involving peripheral blood samples and quantified APA using the DaPars2. We developed a scoring framework to identify key immune-related APA events (ImmAPA) and their utility for grouping SLE patients. And we used the Connectivity Map to explore potential differences in drug response across ImmAPA groups and examined these associations in an independent SLE cohort treated with an immunosuppressive drug. Results: SLE patients exhibited a recurrent trend in lengthening of the 3' untranslated region (3'UTR) across cohorts. Twenty key APA regulators showed enhanced associations with these changes in SLE patients. The ImmAPA score can group patients into ImmAPA-high and ImmAPA-low subtypes, reflects activation states, and correlates with disease severity. The ImmAPA score captured complementary transcriptomic variation compared with interferon signature. CMap analysis predicted drugs that could reverse these APA changes, and was supported by follow-up analysis. Conclusions: Our study reveals a recurrent and widespread shift toward 3'UTR lengthening in SLE at peripheral blood transcriptome level. The ImmAPA framework provides a new perspective for SLE patient stratification and offers insights into precision therapeutic strategies in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.